Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Impact of AI-based risk stratification integrating routine laboratory data with age on screening volume and multi-cancer early detection yield.

Mao Mao, Yi Luan, Yong Shen et al. Jun 01, 2026 pp. 10538-10538 10.1200/jco.2026.44.16_suppl.10538

10538 Background: Early cancer detection improves survival, yet population-wide screening remains costly and logistically...

A single-arm, phase 2 study of neoadjuvant mirvetuximab soravtansine and carboplatin for FRα-expressing advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (M25-231; NCT06890338; GOG-3115).

Rebecca Arend, Christine M. Lee, Charles K. Anderson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5633

TPS5633 Background: Folate receptor alpha (FRα) has limited expression on normal tissues but is highly expressed in most h...

Clinicopathologic profile and comparative performance of limited next-generation sequencing and qPCR for detection of <i>RAS/RAF</i> mutations in stage IV colorectal cancer (mCRC).

Soumya Surath Panda, Ayush Dubey, Subhashree Subhasmita Dash et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15576

e15576 Background: The implications of limited next-generation sequencing (NGS) compared with quantitative/real-time PCR (...

Treatment of localized pulmonary pleomorphic adenocarcinoma: A systematic review and meta-analysis.

Muhammad Fareed Khalid, Osama Ewidat, Muzammil Khan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20040

e20040 Background: Pulmonary pleomorphic adenocarcinoma (PPADC) is a rare, aggressive subtype of non-small cell lung cance...

Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adebrelimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC).

Si Shi, Jin Xu, Miaoyan Wei et al. Jun 01, 2026 pp. 4231-4231 10.1200/jco.2026.44.16_suppl.4231

4231 Background: Tumor specific neoantigens are peptides carrying somatic mutations presented by HLA molecules and recogni...

Proglumide, gemcitabine (GEM), and nab-paclitaxel (NAB-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): Results of the phase 1 PROGEM trial.

Jill P. Smith, Marcus Smith Noel, Reetu Mukherji et al. Jun 01, 2026 pp. 4202-4202 10.1200/jco.2026.44.16_suppl.4202

4202 Background: PDAC has a poor prognosis and resistance to therapy due to its desmoplastic and immunosuppressive tumor m...

Failure-to-rescue following acute hepatic decompensation in hospitalized patients with hepatocellular carcinoma in the United States, 2018–2022.

Arman Manjikian, Tajveer Sangha, Aishwarya Hanspal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23119

e23119 Background: In hospitalized oncology populations, mortality may be influenced by failure to rescue after acute dete...

Don’t ask, don’t tell: Missing ECOGS and anticancer treatment, neutrophil-to-lymphocyte ratios, and outcomes in hospitalized patients with solid tumors.

Holly Gwen Prigerson, Christine A. Garcia, Amanda Rosen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24071

e24071 Background: ASCO’s Choosing Wisely campaign has recommended avoiding cancer-directed therapy for patients with ECOG...

Temporal and demographic trends in mortality from multiple myeloma with coexisting mental and behavioral disorders in U.S. adults, 1999–2023.

Irza Shaikh, Sarim Hassan Shahab, Syeda Malika Naqvi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22592

e22592 Background: Multiple myeloma is a plasma cell malignancy with a persistently high mortality rate; when it occurs in...

EU-OPEN: A novel approach for generating European oncology real-world evidence at scale.

Kaushal Desai, Elinor Sawyer, Mieke Van Hemelrijck et al. Jun 01, 2026 pp. 11161-11161 10.1200/jco.2026.44.16_suppl.11161

11161 Background: The European Oncology Platform for Evidence Needs (EU-OPEN) is a strategic initiative to generate high-q...

The prognostic impact of epilepsy in glioblastoma: Insights from a systematic review and meta-analysis.

Amrat Ayaz Ali, ShriMahalakshmi Bollakpalli, Louissa Cidral et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14038

e14038 Background: Epilepsy is a common comorbidity in patients with glioblastoma (GBM) and significantly impacts quality...

Frameworks for improving comprehensive biomarker testing in NSCLC: A multi-stakeholder consensus.

Maureen Frances Zakowski, Juliana Dierks, David Cobden et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23121

e23121 Background: Despite the availability of numerous targeted therapies for NSCLC, significant barriers persist in ensu...

The effects of specialized сardio-oncological care on the duration of TKI therapy.

Elena Shavarova, Olga Kazakova, Elina Khachaturian et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24030

e24030 Background: tyrosine kinase inhibitors (TKIs) often cause arterial hypertension (AH) that leads to dose reduction/w...

Spatial mapping of human colorectal cancer cell states to identify co-targeting opportunities and determinants of drug response.

Gertjan Rasschaert, Zedong Hu, Elena Richiardone et al. Jun 01, 2026 pp. 3140-3140 10.1200/jco.2026.44.16_suppl.3140

3140 Background: Colorectal cancer (CRC) progression relies on multiple mechanistically distinct proliferative and surviva...

Apatinib combined with adebrelimab and GEMOX regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A multicenter, open-label, single-arm, phase II trial.

Changzhen Shang, Dong Chen, Wei Jinxing et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16202

e16202 Background: Immune checkpoint inhibitor combined with chemotherapy have shown improved prognosis compared with chem...

Operationalizing bispecific antibody therapy in community oncology: Capturing insights on clinician preparedness for using off-the-shelf immunotherapy in lymphoma and multiple myeloma.

Carmine Deluca, Michael Beyer, Hans C. Lee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23221

e23221 Background: The emergence of bispecific antibodies as off-the-shelf immunotherapy for diffuse large B-cell lymphoma...

Indirect treatment comparison of cabozantinib vs sunitinib in the treatment of pancreatic neuroendocrine tumors.

Luke Zhao Li, Nathaniel Saul Herman, Achuta Kumar Guddati Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16327

e16327 Background: Pancreatic neuroendocrine tumors vary widely in grade, functionality, growth rate and aggressiveness. P...

First-in-human study of DM005, an anti-EGFR/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors.

Jin-Ji Yang, Meili Sun, Yuping Sun et al. Jun 01, 2026 pp. 8530-8530 10.1200/jco.2026.44.16_suppl.8530

8530 Background: DM005 is a bispecific ADC (BsADC) conjugated to BLD1102, a linker/payload system composed of a linker and...

Characterization of genomic alterations between local breast cancers and cutaneous metastases.

Francesca Thau, Smruthy Sivakumar, Ethan Sokol et al. Jun 01, 2026 pp. 1038-1038 10.1200/jco.2026.44.16_suppl.1038

1038 Background: Cutaneous metastases (CM) are a distinct manifestation of advanced breast cancer (BC), yet their genomic...

Scrambler therapy for painful chemotherapy-induced peripheral neuropathy: Extending the evidence base.

Thomas B. Strouse, Johanna Leskinen, Thomas Valles et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24147

e24147 Background: Chemotherapy-induced peripheral neuropathy (CIPN) burdens patients. Six months after treatment, the inc...

Development and multicenter validation of a machine learning framework for predicting severe myelosuppression in nasopharyngeal carcinoma: Evidence from large-scale real-world data and prospective clinical trials.

Tingxi Tang, Yutong Wang, Xiaoqing Wang et al. Jun 01, 2026 pp. 6023-6023 10.1200/jco.2026.44.16_suppl.6023

6023 Background: Severe treatment-related myelosuppression (Tr-MS) in nasopharyngeal carcinoma (NPC) necessitates dose red...

Urinary creatine riboside for risk stratification of clinically significant prostate cancer.

Daxesh P. Patel, Leila Toulabi, Ashlie Santaliz Casiano et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17149

e17149 Background: Distinguishing clinically significant prostate cancer from indolent disease remains a major challenge i...

National analysis of cancer care for refugees in Moldova during the war in Ukraine (2022–2025).

Horia Vulpe, Artiom Minzatean, Stefania Magidson et al. Jun 01, 2026 pp. 1602-1602 10.1200/jco.2026.44.16_suppl.1602

1602 Background: Following Russia's invasion of Ukraine in February 2022, Moldova, a non-EU country of 2.3 million, had on...

Prognostic stratification of early-stage NSCLC patients using preoperative circulating tumor DNA (ctDNA).

Zhicheng Huang, Daoyun Wang, Jiayue Xu et al. Jun 01, 2026 pp. 8031-8031 10.1200/jco.2026.44.16_suppl.8031

8031 Background: Curative-intent surgery for early-stage non-small-cell lung cancer (NSCLC) is followed by relapse in appr...

Dual-microbial signature as a predictor of postoperative colorectal cancer recurrence.

Pancheng Chen, Yanlei Ma, Jinming Li Jun 01, 2026 pp. 3611-3611 10.1200/jco.2026.44.16_suppl.3611

3611 Background: Current surveillance strategies for postoperative recurrence in colorectal cancer predominantly depend on...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page